Regeneron/Sanofi, Amgen PCSK9 Rivalry Continues, But Not In US Courts
Federal Circuit Affirms Invalidation Of Two Amgen Patents
The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.
